Zacks Research Analysts Increase Earnings Estimates for GSK

GSK plc (NYSE:GSK) – Equities researchers at Zacks Research increased their FY2027 earnings estimates for GSK in a research note issued to investors on Tuesday, March 25th. Zacks Research analyst E. Bagri now expects that the pharmaceutical company will earn $5.05 per share for the year, up from their previous estimate of $5.04. The consensus estimate for GSK’s current full-year earnings is $4.14 per share.

GSK (NYSE:GSK) last released its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%.

GSK has been the subject of a number of other reports. Morgan Stanley started coverage on GSK in a report on Wednesday, February 12th. They issued an “equal weight” rating for the company. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 7th. Seven research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Stock Down 0.8 %

Shares of NYSE:GSK opened at $38.28 on Thursday. The firm has a fifty day moving average of $37.01 and a 200 day moving average of $36.81. GSK has a 52-week low of $31.72 and a 52-week high of $45.93. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78. The firm has a market capitalization of $79.24 billion, a PE ratio of 24.08, a price-to-earnings-growth ratio of 1.12 and a beta of 0.58.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Shareholders of record on Friday, February 21st will be paid a $0.3932 dividend. This is a boost from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 dividend on an annualized basis and a yield of 4.11%. The ex-dividend date of this dividend is Friday, February 21st. GSK’s payout ratio is 98.74%.

Institutional Trading of GSK

A number of institutional investors have recently modified their holdings of the company. Dodge & Cox lifted its holdings in GSK by 0.5% in the 4th quarter. Dodge & Cox now owns 68,440,912 shares of the pharmaceutical company’s stock worth $2,314,672,000 after buying an additional 353,749 shares during the period. FMR LLC lifted its stake in GSK by 82.1% in the fourth quarter. FMR LLC now owns 52,823,032 shares of the pharmaceutical company’s stock worth $1,786,475,000 after acquiring an additional 23,814,104 shares during the period. Primecap Management Co. CA lifted its stake in GSK by 70.1% in the fourth quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company’s stock worth $854,349,000 after acquiring an additional 10,407,905 shares during the period. Fisher Asset Management LLC boosted its holdings in GSK by 1.4% in the fourth quarter. Fisher Asset Management LLC now owns 18,836,797 shares of the pharmaceutical company’s stock valued at $637,061,000 after acquiring an additional 259,867 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its position in GSK by 0.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,566,922 shares of the pharmaceutical company’s stock valued at $255,914,000 after purchasing an additional 35,134 shares during the period. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.